Label-free Assessment of Complement-Dependent Cytotoxicity of Therapeutic Antibodies via a Whole-Cell MALDI Mass Spectrometry Bioassay

Stefan Schmidt,Alexander Geisel,Thomas Enzlein,Björn C. Fröhlich,Louise Pritchett,Melanie Verneret,Christian Graf,Carsten Hopf

DOI: https://doi.org/10.1101/2024.05.03.592336

2024-05-05

Abstract:Potency assessment of monoclonal antibodies or corresponding biosimilars in cell-based assays is an essential prerequisite in biopharmaceutical research and development. However, cellular bioassays are still subject to limitations in sample throughput, speed, and often need costly reagents or labels as they are based on an indirect readout by luminescence or fluorescence. In contrast, whole-cell Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF) Mass Spectrometry (MS) has emerged as a direct, fast and label-free technology for functional drug screening being able to unravel the molecular complexity of cellular response to pharmaceutical reagents. However, this approach has not yet been used for cellular testing of biologicals. In this study, we have conceived, developed and bench-marked a label-free MALDI-MS based cell bioassay workflow for the functional assessment of complement-dependent cytotoxicity (CDC) of Rituximab antibody. By computational evaluation of response profiles followed by subsequent feature annotation via fragmentation analysis and trapped ion mobility MS, we identified adenosine triphosphate and glutathione as readily MS-assessable metabolite markers for CDC and demonstrate that robust concentration-response characteristics can be obtained by MALDI-TOF MS. Statistical assay performance indicators suggest that whole-cell MALDI-TOF MS could complement the toolbox for functional cellular testing of biopharmaceuticals.

Biochemistry

What problem does this paper attempt to address?

The problem this paper attempts to address is the development of a label-free whole-cell matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) bioassay method for assessing the complement-dependent cytotoxicity (CDC) of therapeutic antibodies. Traditional methods such as fluorescence or luminescence detection require expensive reagents and labels, and have low sample throughput and slow speed. In contrast, MALDI-TOF MS technology offers the advantages of being rapid, direct, and label-free, and can reveal the molecular complexity of cellular responses to drugs. However, this technology has not yet been applied to the functional testing of biopharmaceuticals. Therefore, this study aims to design and validate a CDC bioassay method based on MALDI-TOF MS to evaluate the potency of monoclonal antibodies (such as rituximab). Specifically, the main objectives of this study include: 1. Developing a label-free MALDI-TOF MS bioassay method to assess the CDC activity of monoclonal antibodies. 2. Identifying suitable metabolite markers (such as ATP and glutathione) through computational analysis of response characteristics combined with fragment analysis and ion mobility spectrometry. 3. Validating the reliability and accuracy of this method by comparing it with traditional luminescence methods. 4. Evaluating the potential application of this method in high-throughput screening and biopharmaceutical development.

Label-free Assessment of Complement-Dependent Cytotoxicity of Therapeutic Antibodies via a Whole-Cell MALDI Mass Spectrometry Bioassay

Label-free assessment of complement-dependent cytotoxicity of therapeutic antibodies via a whole-cell MALDI mass spectrometry bioassay

A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies

Integration of an In Situ MALDI-Based High-Throughput Screening Process: A Case Study with Receptor Tyrosine Kinase c-MET

Microfluidic capillary electrophoresis - mass spectrometry for rapid charge-variant and glycoform assessment of monoclonal antibody biosimilar candidates

A high-throughput MALDI-TOF MS biochemical screen for small molecule inhibitors of the antigen aminopeptidase ERAP1

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells

Direct glycosylation analysis of intact monoclonal antibodies combining ESI MS of glycoforms and MALDI-in source decay MS of glycan fragments

Automated MALDI Target Preparation Concept: Providing Ultra-High-Throughput Mass Spectrometry–Based Screening for Drug Discovery

Automated High-Throughput Matrix Assisted Laser Desorption Ionization Mass Spectrometry Methodology for Formulation Assessment of Polyethylene-Glycol-Conjugated Cytokine Proteins

Online multimethod platform for comprehensive characterization of monoclonal antibodies in cell culture fluid from a single sample injection - Intact protein workflow

A Versatile Flow-Based Assay for Immunocyte-Mediated Cytotoxicity.

Chemical Derivatization Enables MALDI-TOF-Based High-Throughput Screening for Microbial Trimethylamine (TMA)-Lyase Inhibitors

M2ara: unraveling metabolomic drug responses in whole-cell MALDI mass spectrometry bioassays

MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures

Development of a chromatography-free method for high-throughput MS-based bioanalysis of therapeutic monoclonal antibodies.

MALDI-TOF-Based Affinity Selection Mass Spectrometry for Automated Screening of Protein-Ligand Interactions at High Throughput

Evaluation of Targets for Maytansinoid ADC Therapy Using a Novel Radiochemical Assay

Rapid antibody conformational screening by matrix-assisted laser desorption/ionization hydrogen-deuterium exchange mass spectrometry

Quantitative Approach for Protein Analysis in Small Cell Ensembles by an Integrated Microfluidic Chip with MALDI Mass Spectrometry

Systematic Optimization of the iMALDI Workflow for the Robust and Straightforward Quantification of Signaling Proteins in Cancer Cells